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Abstract: Biomarkers are biomolecules that serve as indicators of biological and pathological processes, or physiological 
and pharmacological responses to a drug treatment. Because of the high abundance of albumin and heterogeneity of plasma 
lipoproteins and glycoproteins, biomarkers are difﬁ  cult to identify in human serum. Due to the clinical signiﬁ  cance the 
identiﬁ  cation of disease biomarkers in serum holds great promise for personalized medicine, especially for disease diagno-
sis and prognosis. This review summarizes some common and emerging proteomics techniques utilized in the separation 
of serum samples and identiﬁ  cation of disease signatures. The practical application of each protein separation or identiﬁ  ca-
tion technique is analyzed using speciﬁ  c examples. Biomarkers of cancers of prostate, breast, ovary, and lung in human 
serum have been reviewed, as well as those of heart disease, arthritis, asthma, and cystic ﬁ  brosis. Despite the advancement 
of technology few biomarkers have been approved by the Food and Drug Administration for disease diagnosis and prog-
nosis due to the complexity of structure and function of protein biomarkers and lack of high sensitivity, speciﬁ  city, and 
reproducibility for those putative biomarkers. The combination of different types of technologies and statistical analysis 
may provide more effective methods to identify and validate new disease biomarkers in blood.
Abbreviations: 2-DE, two-dimensional gel electrophoresis; 2DLC-MS, two-dimensional liquid chromatography mass 
spectrometry; CA 15.3, cancer antigen 15.3; CA 19–9, cancer antigen 19–9, a tumor-associated antigen; CA125, cancer 
antigen 125, a mucin-like protein; CEA, carcinoembryonic antigen; CF, Cystic Fibrosis; CRP, C-reactive protein; ELISA, 
enzyme-linked immunosorbent assay; ESI-MS/MS, electrospray ionization tandem mass spectrometry; FDA, Food and 
Drug Administration; IPG, immobilized pH gradient; MALDI-TOF-MS, matrix-assisted laser desorption-ionization time-
of-ﬂ  ight mass spectrometry; MDLC, multidimensional liquid chromatography; MUC, mucin; MudPIT, multi-dimensional 
protein identiﬁ  cation technology; OA, osteoarthrosis; pI, isoelectric point; PSA, prostate-speciﬁ  c antigen; RA, rheumatoid 
arthritis; RP-HPLC, reversed-phased-high performance liquid chromatography; RPLC, reversed phase liquid chromatog-
raphy; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SEC, size exclusion chromatography; 
SELDI, surface-enhanced laser desorption ionization; SELDI-TOF, surface-enhanced laser desorption ionization-time of 
ﬂ  ight. 
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1. Introduction
1.1 Proteomics
Proteomics is the science and technology of separating and identifying proteins from crude biological 
samples. It is mostly signiﬁ  cant when differentially-expressed proteins between two samples that belong 
or that are subject to different conditions are identiﬁ  ed. This identiﬁ  cation will allow for the character-
ization of biological roles, clariﬁ  cation of biological mechanisms, and identiﬁ  cation of therapeutic 
targets and biomarkers. The ﬁ  rst step of a proteomic study requires almost always the separation of 
proteins using electrophoresis or chromatography techniques followed by the identiﬁ  cation steps that 
are performed using mass spectrometry. The latter measures accurately the masses of peptides generated 
from the digestion of the protein by trypsin or another enzyme followed by the use of software that scan 
the different protein databases available to identify the protein. This identiﬁ  cation is based on the infor-
mation collected about this protein throughout the study including but not limited to isoelectric point, 
molecular mass, peptide masses, and specie of the biological sample. It is preferable–even required 
sometimes–to use immunoblotting techniques or N-terminal sequencing to validate the identity of the 
proteins. Proteomics studies can be applied on any protein mixture extracted from any organism including Biomarker Insights 2007: 2 22
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plant, bacterial, and animal cells. Proteomics strat-
egies have been used to identify disease-speciﬁ  c 
protein markers called biomarkers that could 
provide the basis for the development of new 
diagnosis methodologies, treatments, and early 
disease detection (Hanash, 2000; Somiari et al. 
2003).
1.2 Clinical proteomics 
and biomarkers
The term clinical proteomics refers to “the applica-
tion of available proteomics technologies to current 
areas of clinical investigation” (Clarke et al. 2003). 
Many diseases manifest themselves through severe 
changes in human physiology, which forms the 
basis for clinical chemistry and bestows its value 
in diagnoses and subsequent therapeutic interven-
tions (Bischoff and Luider, 2004). Clinical 
proteomics includes the global analysis of proteins 
expressed by the genome of an organism, with the 
typical aim being the evaluation of quantitative 
changes that occur as a function of disease, treat-
ment, or environment (Somiari et al. 2003). 
Proteomics strategies have been used to recog-
nize disease-specific protein markers called 
biomarkers that could provide the basis for the 
development of new diagnosis methodologies, 
treatments, and early disease detection (Hanash, 
2000; Somiari et al. 2003). A biomarker is deﬁ  ned 
as “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological 
processes, pathological processes, or pharmaco-
logical responses to a therapeutic intervention” 
(Atkinson et al. 2001).
 The degree to which biomarkers reﬂ  ect clinical 
outcomes judges their effectiveness. As biomarkers 
have different characteristics there should be statis-
tical requirements that determine the usefulness of 
biomarkers as evaluations of disease progression or 
outcomes in clinical trials (Cummings, 2005). Those 
requirements should include statistical dispersion, 
detailed information on target populations, and 
speciﬁ  city of the biomarker. Generally, an ideal 
biomarker is expected to be: able to detect a funda-
mental feature of a speciﬁ  c disease; validated in and 
conﬁ  rmed by those speciﬁ  c disease cases; precise, 
able to detect the early stages of this speciﬁ  c disease 
and distinguish it from other similar disease cases 
or family members of that disease; simple to 
perform; reliable; non-invasive; and inexpensive if 
possible (Anon et al. 1998; Gao et al. 2005).
 To identify new biomarkers of a certain disease 
in vitro, a three component analytical strategy was 
developed, which consists of (I) a cell line as the 
pre-clinical model, (II) a set of ﬁ  ve well-studied 
drugs, three of which had been found in humans 
to elicit that disease, and (III) implementation of 
multi-dimensional protein identification tech-
nology (MudPIT) (see 3.3) to perform semi-
quantitative analysis and identify protein biomarker 
candidates (Gao et al. 2005). MudPIT was chosen 
due to the demonstration of its usefulness in the 
identiﬁ  cation as well as semi-quantiﬁ  cation (rela-
tive changes/differential trends in protein abun-
dance) of large numbers of proteins, both in vivo 
and in vitro (Washburn et al. 2001; Pang et al. 
2002; Gao et al. 2003; Gao et al. 2004). This 
biomarker-identiﬁ  cation stage generates a large 
list of biomarkers. Upon passing through a crucial 
second stage, a rate determining one, only the most 
appropriate subset of biomarker-candidates will 
be further tested by traditional immunoassays to 
identify and verify an ideal biomarker or the most 
credible biomarker for a speciﬁ  c disease according 
to aforementioned criteria (Gao et al. 2005).
1.3 Signiﬁ  cance of proteomics of 
human samples
Mammalian samples are the most studied species 
in terms of protein proﬁ  ling studies. In vitro culture 
of mammalian cell lines is an important resource 
for research, and have been used for disease-related 
studies (Tedeschi et al. 2005; Liu et al. 2005; 
Bianchi et al. 2005; An et al. 2005) as well as 
technology related ones (Hamler et al. 2004; Zhu 
et al. 2004; Buchanan et al. 2005) . The protein 
proﬁ  les of cancerous cell lines have been compared 
to the proﬁ  les of normal cell lines (O’Neill et al. 
2003). While tumor-derived cell lines can be useful 
for initial studies (Wu et al. 2002), each line 
displays a unique evolution that may not truly 
mimic real in vivo conditions (Ornstein et al. 
2000a). A comparison between human prostate cell 
lines with tumor cells from prostate patients 
showed signiﬁ  cant altered protein proﬁ  les (Ornstein 
et al. 2000b). Differentially-expressed proteins 
identiﬁ  ed in human in vivo cancerous tissues when 
compared to their normal counterparts are by far 
more signiﬁ  cant than in vitro ones. A large number 
of studies have been successful in identifying 
protein signatures of a disease or a condition from 
in vivo tissues (Wulfkuhle et al. 2002; Tribl et al. Biomarker Insights 2007: 2 23
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2005), as well as patient serum samples (Broeck-
aert et al. 2000; Hathaway et al. 2005; Ahn et al. 
2005). These differentially-expressed proteins are 
considered either the cause or the effect of the 
physiological change in the organism. Many 
published proteomic studies of human tumor 
tissue are associated with weaknesses in tumor 
representation, sample contamination by non-
tumor cells and serum proteins. Studies often 
include a moderate number of tumors which may 
not be representative of clinical materials (Alaiya 
et al. 2005).
1.4 Human serum
Human serum is the clear portion of the human’s 
body ﬂ  uid that separates from blood upon clotting. 
This clear ﬂ  uid provides moisture to the serous 
membranes in the human body. It contains 60–80 
mg/mL of proteins in addition to various small 
molecules including amino acids, lipids, salts, and 
sugars (Burtis et al. 2001). Normal human serum 
mainly contains the following proteins: IgG, IgM 
(Ekdahl et al. 1994), IgA, haptoglobulin, albumin 
(Era et al. 1995), transferrin (Burtis et al. 2001), 
α1-anti-trypsin, ﬁ  brinogen, α2-Macroglobulin, and 
complement C3, those account for >95% of total 
serum proteins (Anderson and Anderson, 2002), 
many of which are synthesized and secreted, shed, 
or lost from cells and tissues throughout the
body (Schrader and Schulz-Knappe, 2001; 
Kennedy, 2001). 
Analysis of the human serum proteome, espe-
cially for biomarkers,
 has great potential for diag-
nosis and early detection of human
 disease. One 
of the difﬁ  culties to identifying a speciﬁ  c marker 
in the human serum is the low abundance of 
proteins secreted in the serum as a result of the 
disease when compared to the high concentration 
of albumin, resulting from daily synthesis of
 ~12 g 
in the liver and a half-life of about 21 days 
(McFarlane et al. 2000), that constitutes more than 
50% (w/w) of the total amount of proteins in the 
serum. Knowing the complexity of
 the human 
proteome and the broad dynamic range in abun-
dance
 of individual proteins (e.g. albumin, immu-
noglobulin), there is a need for sample treatment 
prior to biomarker identiﬁ  cation and is feasible 
using different analytical techniques. A prefrac-
tionation step to eliminate albumin from the serum 
is therefore required prior to the proteomic study 
(Lee et al. 2006a).
1.5 Protein properties
Proteins are composed of covalently bound amino 
acids. There are 20 different amino acids generating 
an inﬁ  nite number of possible proteins. Several 
protein physical properties should be taken into 
consideration for a successful proteomic project. 
These properties are used to separate and to identify 
proteins from crude biological samples. Based on 
the side chain properties, amino acids of a protein 
can form unstable interactions through electrostatic, 
hydrogen bonding, and hydrophobic affinities. 
These interactions result in the folding of proteins 
that hinders their separation and identiﬁ  cation neces-
sitating the introduction of several reagents to the 
protein solubilizing buffer to break these interac-
tions. Once these interactions are neutralized, the 
protein becomes unfolded (denatured). After dena-
turing the proteins, the remaining physical properties 
are used to separate and purify these proteins.
1.5.1 Isoelectric point (pI) 
Proteins are amphoteric molecules: they can carry 
positive, negative or a neutral charge. At a certain 
pH, the number of positive charges is equal to the 
number of negative charges: this pH is equal to the 
pI of the protein. The amino acids that affect the 
value of the protein isoelectric point the most are 
those with ionizable side chains: Arginine, Tyro-
sine, Lysine, Cysteine, Histidine, Glutamic acid, 
and Aspartic acid. Proteins can be separated based 
on their isolelectric point using ion exchange chro-
matography as well as immobilized pH gradient 
polyacrylamide gels (see 2.3.1).
1.5.2 Hydrophobicity
The highly hydrophobic amino acid side chains 
are those of: Valine, Leucine, Isoleucine, Methio-
nine, Phenylalanine, Tryptophan, and Cysteine. 
Proteins can be separated based on their hydropho-
bicities using Reversed-Phased High performance 
Liquid Chromatography (RP-HPLC). The 
stationary phase used for RP-HPLC is composed 
of silica beads with carbon chains linked to it. The 
protein mixture is injected in the column and then 
an acetonitrile gradient is imposed. More hydro-
phobic proteins require higher concentrations of 
acetonitrile for their elution (see 2.2.2). 
1.5.3 Molecular mass (Mr) and size
Proteins can be composed of as few as tens of 
amino acids and as many as thousands. Most of Biomarker Insights 2007: 2 24
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the time, denatured proteins having a higher 
number of amino acids will have a bigger size and 
a higher Mr. Sodium Dodecyl Sulfate Polyacryl-
amide gel electrophoresis (SDS-PAGE) (see 2.3.1) 
as well as size exclusion chromatography can be 
used to separate proteins based on their size or Mr. 
The approximate Mr can be measured using these 
techniques. To measure the exact Mr of proteins a 
mass spectrometer should be used. 
2. Serum Protein Separation
2.1 Sample treatment using 
commercially-available kits
The presence of highly abundant albumin and 
immunoglobulins that constitute approximately 
60–97% of the total serum proteins gave the urge 
for using special kits to eliminate those highly 
abundant proteins to allow the visualization of 
low abundant proteins, such as using Cibacron 
blue F3GA based-resin (Ahmed et al. 2005) and 
antibody-related methods. 
Unfortunately, it was shown that Cibacron blue 
F3GA based-resin method will clear, not just the 
albumin, but also every protein having the same 
pI and those with a high afﬁ  nity to Cibacron Blue 
dye’s planar ring structure (Ahmed et al. 2003) or 
due to the protein’s dinucleotide fold (Lollo et al. 
1999). The major disadvantage of using antibody 
afﬁ  nity methods is the loss of the low-abundance 
proteins bound to high-abundance carrier proteins; 
this loss was reported to be up to 38 proteins in 
one study (Yocum et al. 2005).
2.2 Alternative analytical techniques 
for serum treatments
2.2.1 Ion exchange chromatography
Ion exchange chromatography is a high resolution 
and capacity, easily used technique for separating 
proteins according to their charge. As proteins are 
charged molecules, adding them in a column will 
cause an interaction with the resin displacing 
mobile counter ions that are bound to the resin 
depending on the overall charge from the amino 
acids in the protein, on the pH of the buffering 
solution, and on the distribution of charged mole-
cules on the folded protein’s surface. If the pH is 
above a protein’s pI, the protein will bind to anion 
exchangers (e.g. Diethylaminoethyl); below its pI 
it will bind to cation exchangers (e.g. Carboxy-
methyl). At its pI, a protein will not bind to either 
a cationic or an anionic exchanger. So by using 
either a cation or an anion exchanger and selecting 
the appropriate pH, the target protein will bind to 
the beads in the process of purifying this protein. 
The typical elution modes in Ion exchange chro-
matography are the salt gradient (Shan and 
Anderson, 2002; Winnik, 2005) or the change of 
the eluent pH (Shan and Anderson, 2002; Alaiya 
et al. 2005). Ion exchange chromatography was 
reported to be utilized as a fractionating technique 
(Qin et al. 2005; Sahab Ziad et al. 2005) and as an 
analysis method for serum proteins (Pappas et al. 
2004).
2.2.2 Reversed-phase Liquid 
Chromatography
High performance reversed phase liquid chroma-
tography (RPLC) is a widely accepted easy to use 
technique for the separation of peptides, proteins 
and other biopolymers (Regnier, 1983). It has great 
resolving power and there is ease of concentrating 
collected fractions, as many RPLC separations 
employ volatile eluents. The mobile phase, polar 
aqueous-organic mixtures such as acetonitrile-
water or methanol-water (solvent), in RPLC is 
signiﬁ  cantly more polar then the stationary phase 
(Anon, 2000), non-polar hydrocarbons, waxy 
liquids or bonded hydrocarbons (such as C4, C8, 
C18, and the like). The interaction of the non-polar 
components of the solutes (mixture of compo-
nents = Experimented Sample) and the non-polar 
stationary phase cause the retention of the target 
component on the matrix, while the elution of the 
target molecule is achieved by utilizing a buffer 
(another solvent) of decreasing polarity. Most 
commonly used sorbents in RPLC are packed with 
chemically bonded octadecylsilyl coated silica, to 
which various functionalities such as the alkyl (C18 
and C8), aromatic phenyl, and cyano and amino 
groups are widely bound. Other popular bonded 
phase columns have cyanopropyl, octasilyl, or 
phenylsilyl packings. 
 To separate large numbers of proteins with 
sufﬁ  cient resolution, a 1.5 µm non porous silica-
RPLC column is used. The Non-porous silica 
allows rapid separations of large numbers of 
proteins with high recovery compared to porous 
columns (Lubman et al. 2002). This separation is Biomarker Insights 2007: 2 25
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compatible with the chromatofocusing (also known 
as anion exchange chromatography) separation. 
The samples that would be separated by non porous 
silica reversed phase HPLC are the fractions 
collected from the ﬁ  rst chromatofocusing separa-
tion. These fractions’ pH will be neutralized using 
HCl or NaOH, vacuum centrifuged, their precipi-
tates will be reconstituted in water, 0.1% Triﬂ  uo-
roacetic acid, and 0.05% Octylglucopyranoside, 
and afterward will be subjected to Electrospray 
Mass spectrometry. 
RPLC is used to fractionate serum proteins 
(Morris et al. 2004; Marshall et al. 2004; Qin et al. 
2005; Martosella et al. 2005; Sheng et al. 2006). This 
method allows for a high protein recovery and is 
compatible with other separation techniques and can 
be coupled with mass spectrometry (see 2.3.2).
2.2.3 Size Exclusion Chromatography
Size exclusion chromatography (SEC) is a general, 
not a high-resolution, technique that separates 
mixtures based on the molecular size of the compo-
nents, such as biomolecules and organic polymers 
and was used as one of the several means of frac-
tionating serum proteins (Pieper et al. 2003; Kuhn 
et al. 2004). Adjustment of the porosity of the gel 
can exclude all molecules above a certain size, 
therefore, the solute retention time depends sensi-
tively on the solute’s size (Bloustine et al. 2003). 
A line of porous silica-based and polymer-based 
SEC matrices is tailored for fast, high resolution 
of large and small biomolecules and organic poly-
mers. The trade names for gels available commer-
cially in a broad range of porosities are Sephadex 
and Sepharose (Adrados et al. 2001). For the sepa-
ration of biomolecules in aqueous systems, SEC 
is referred to as gel ﬁ  ltration chromatography, 
while the separation of organic polymers in non-
aqueous systems is known as gel permeation 
chromatography.
Investigation of the binding of Human Neutro-
phil Peptides -1, -2 and -3 to high mass plasma 
proteins was performed using SEC. These serum 
peptides may serve as blood markers for colon 
cancer in combination with Surface Enhanced 
Laser Desorption/Ionisation—Time Of Flight/
Mass spectrometry (SELDI-TOF/MS) (Albrethsen 
et al. 2005). This strategy may also be used for other 
smaller markers. The advantages and disadvantages 
of methodologies of serum sample treatment and 
prefractionation are summarized in Table 1.
2.3 Protein separation after sample 
treatment
2.3.1 Two-dimensional Polyacrylamide Gel 
Electrophoresis (2-DE) 
Two-dimensional polyacrylamide gel electropho-
resis (2-DE) is an analytical technique that simul-
Table 1. Advantages and Disadvantages of Albumin Elimination versus Serum Fractionation.
Techniques               Advantages                                Disadvantages
     Cibacron Blue F3GA  - Fast  - Loss of proteins 
Albumin       bound to albumin
Elimination  Antibody-Based  - Does not require
Techniques  Albumin Elimination  specialized 
     instrumentation      
Serum  Anion Exchange  - High Recovery Rate
Fractionation  Chromatography 
Techniques    - Can be coupled with  - Requires specialized
   Reversed-Phased High  other separation   Instrumentation    
   Performance  Liquid  techniques
   Chromatography 
      Size Exclusion  - Can be optimized to   - Time consuming   
   Chromatography  fractionate the serum 
      sample into many
      fractions each enriched
      with target proteinsBiomarker Insights 2007: 2 26
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taneously separates thousands of proteins (Anderson 
and Anderson, 1977; Lilley et al. 2002) and allows 
comparative protein proﬁ  ling in different crude 
biological samples. Although labor intensive, this 
technique is still the predominant method for 
protein profiling (Pandey and Mann, 2000; 
Westbrook et al. 2001; Huang et al. 2005).
A protein placed in a medium with a pH 
gradient and subjected to an electric ﬁ  eld will 
move toward the electrode of opposite charge and 
stops when it arrives at the point in the pH 
gradient equal to its pI (Tribl et al. 2005; Sheng 
et al. 2006). Immobilized pH Gradient (IPG) 
strips offer the advantage of gradient stability over 
extended focusing runs, where its gradient’s pH 
is related with sets of acrylamido buffers that can 
form almost any conceivable pH gradient 
(Bjellqvist et al. 1982). Proteins resolved in IPG 
strips in the ﬁ  rst dimension will be applied to 
second-dimension gels and separated by molec-
ular mass perpendicularly to the ﬁ  rst dimension 
(O’Farrell, 1975). The pores of the second dimen-
sion gel sieve proteins according to size because 
dodecyl sulfate coats all proteins essentially in 
proportion to their mass. The net effect is that 
proteins migrate as ellipsoids with a uniform 
negative charge-to-mass ratio, with mobility 
related logarithmically to mass. Proteins will 
therefore be separated horizontally based on their 
isoelectric point and vertically based on their 
molecular mass (Mr).
Although imperfect, 2-DE is the only analytical 
technique that simultaneously separates thousands 
of proteins and allows comparative protein 
profiling between different crude biological 
samples, for instance, proteins in hepatocellular 
carcinoma serum have been characterized by 
utilizing 2-DE separation (Lee et al. 2006b). 2-DE 
is incapable of detecting the majority of protein 
components, such as very large or small proteins, 
membrane-associated proteins, extremely hydro-
phobic, acidic or basic proteins and proteins found 
in low abundance within the cell (Corthals et al. 
2000; Gygi et al. 2000a; Gygi et al. 2000b; Graves 
and Haystead, 2002; Gorg et al. 2004; Chignard 
and Beretta, 2004). The ones that are detected are 
mainly the high abundant ones (Dos Remedios et al. 
2003). The limitation in protein loading on the 
IPG strips as well as the magnitude of protein 
abundance within a cell that differ by up to 10 
orders of magnitude are the main cause for this 
discrimination. 
2.3.2 Two-dimensional Liquid Chromatography 
Mass Spectrometry (2DLC-MS)
Proﬁ  ling of proteins using 2-DLC can be performed 
(Lubman et al. 2002) using ion exchange chromatog-
raphy or chromatofocusing (Whitelegge, 2005) to 
separate proteins based on their charge and Reversed-
Phase Liquid Chromatography- Electrospray 
Ionization Mass spectrometer to separate proteins 
based on their hydrophobicities in the second 
dimension and measure their exact Mr  . For 
instance, the application of 2-DLC was used: as 
an isolation strategy (Lam et al. 2005), to generate 
protein proﬁ  les (Liao et al. 2004), and for prote-
omic analysis (Hamler et al. 2004) for proteins in 
serum.
More recently in proteomics, aiming for the 
optimization of protein separation methods and 
selective depletion of the higher abundance 
proteins, such as immunoglobulins (e.g. IgG) and 
albumin, has led researchers to separate intact 
proteins in the liquid phase with multidimensional 
liquid chromatography (MDLC). MDLC is 
performed utilizing separation ﬁ  rst by chromato-
graphic focusing and second by reversed phase, 
and followed by mass spectrometric detection and 
identiﬁ  cation (Wall et al. 2000; Gygi et al. 2002; 
Pieper et al. 2003; Rose et al. 2004; Fung et al. 
2004; Sheng et al. 2006). Finally, database is 
searched by the SEQUEST algorithm. This whole 
procedure is referred to as multidimensional 
protein identiﬁ  cation technology (MudPIT) that will 
be discussed later in the review (Washburn et al. 
2001) (see 3.3). In proteomics studies, MDLC 
successfully complements 2-D electrophoresis as 
it overcomes difficulties encountered during 
analysis of samples containing proteins spreading 
over a large molecular weight range (Washburn et al. 
2001; Han et al. 2001) or proteins with immoderate 
isoelectric points (pI). 
2.3.3 Surface-enhanced Laser Desorption 
Ionization (SELDI)
Another versatile and convenient proteomics tool 
that allows semi quantitative analysis of numerous 
proteins in most biological samples is the surface-
enhanced laser desorption ionization-time of ﬂ  ight 
(SELDI-TOF) system. Complex biological samples 
can be analyzed and compared to detect differentially-
expressed proteins in the samples that are selec-
tively retained by using different chromatographic 
surfaces (Tang et al. 2004), “chip” (a thin strip of Biomarker Insights 2007: 2 27
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aluminum, which has eight small places for 
loading samples), such as immobilized metal 
affinity capture for capturing metal-binding 
proteins, hydrophobic for reversed-phase capture, 
anion and cation exchange surfaced, and pre-
activated surfaces to examine receptor-ligand, 
antibody-antigen, DNA-protein, and the like. The 
number of proteins quantiﬁ  ed in each sample is 
dependent on the tissue and the chip surface. Using 
MS, proteins retained on the array get analyzed 
generating a proﬁ  le of the analyzed proteome. This 
instrument has a combination of software, Pattern 
Recognition Software and one for comparing 
groups of biological samples, which permits the 
detection of subtle differences between groups of 
samples allowing the detection and assessment of 
sensitivity/specificity of a very wide range of 
biomarkers. An example of known software used 
is the Ciphergen Biosystems software (Vermeulen 
et al. 2005). For data presentation, the two useful 
formats are the grey-scale and the raw spectrum 
(the former represents a stained one-dimensional 
electrophoresis gel, hence the name “gel-view”). 
Currently SELDI have been used for evaluating 
serum ﬁ  nding it useful for the discovery and iden-
tiﬁ  cation of potential biomarkers (Li et al. 2002; 
Petricoin et al. 2002a; Qu et al. 2002; Petricoin et al. 
2002b; Petricoin et al. 2002c; Issaq et al. 2002; 
Miguet et al. 2006). Although limitations during
 
large proﬁ  ling experiments, where some observa-
tions noted that spectra can vary based on analyt-
ical
 factors (such as the time of processing, issues 
in the reproducibility of SELDI (Petricoin et al. 
2002a; Deng et al. 2003; Diamandis, 2003), and 
usually unidentiﬁ  ed individual proteins (Chignard 
and Beretta, 2004)), there are advantages that 
include prior to analysis removal of components 
(salts or detergents) that commonly cause problems 
with other analytical tools, thus leaving only those 
proteins that are actively interacting with the spot 
surfaces to be analyzed in the ProteinChip Reader 
(Romer et al. 2002).
3. Serum Protein Identiﬁ  cation
3.1 Mass spectrometry techniques
3.1.1 Matrix-Assisted Laser Desorption-
Ionization Time-of-Flight Mass Spectrometry 
(MALDI-TOF-MS): Peptide mass measurement
Proteins are usually identiﬁ  ed utilizing Matrix-
Assisted Laser Desorption-Ionization Time-of-
Flight Mass Spectrometry (MALDI-TOF-MS) 
(Binz et al. 2003; Aebersold and Mann, 2003; 
Ferguson and Smith, 2003; Heck and Krijgsveld, 
2004; Feuerstein et al. 2005). After 2-DE, spots are 
excised and treated with TPCK-treated trypsin. 
While in case of using 2-DLC, the resulting frac-
tions collected in the second dimension of the 
separation are vacuum dried and incubated with 0.5 
µg/mL TPCK-treated trypsin. The peptides gener-
ated from the trypsin digestion are ﬁ  rst mixed with 
a matrix (α-cyano-hydroxycinnamic acid) (matrix 
application described by (Karas and Hillenkamp, 
1988; Tanaka et al. 1988)), which should consist of 
a 100–1000-fold molar excess of the matrix over 
the analyte (Schiller et al. 1999). This mixture is 
then spotted onto a plate and allowed to evaporate 
forming crystals that will be analyzed by the mass 
spectrometer and time-of-flight analyzer. This 
analysis provides for measurement of the peptide 
fragment masses generated by trypsin digestion of 
the protein where the mass resolution is a measure 
of a spectrometer’s capability to produce separate 
signals of ions of similar mass (Hillenkamp et al. 
1991). Finally, having obtained the molecular 
weight, pI, and peptide ﬁ  ngerprints of the protein 
of interest, identiﬁ  cation of the protein should be 
possible using the Peptident tool that scans the 
Swiss-Prot protein database (UniProtKB) for pos-
sible matches. 
MALDI-TOF-MS has been used to analyze serum 
biomarkers. For instance, it was used in combination 
with porous silicon nanovial arrays to achieve high-
speed biomarker identiﬁ  cation (Finnskog et al. 2006). 
In another study, 4 protein spots signiﬁ  cantly down-
regulated in grade 3 ovarian cancer patients were 
identiﬁ  ed as isoforms of transferrin precursor using 
MALDI-TOF (Ahmed et al. 2005). Recently, its 
combination with derivatized cellulose particles repre-
sented a simple, economical, and rapid approach to 
generate serum protein proﬁ  les for biomarker identi-
ﬁ  cation (Feuerstein et al. 2005). Furthermore, one 
study proved that the analysis of MALDI-TOF/MS 
data using proteomic spectral pattern recognition 
software derived a distinctive molecular signature of 
multiple sclerosis (Avasarala et al. 2005).
3.1.2 Electrospray Ionization Tandem Mass 
Spectrometry (ESI-MS/MS)
Electrospray ionization (Dole et al. 1968) tandem 
mass spectrometry (Yamashita and Fenn, 1984) Biomarker Insights 2007: 2 28
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(ESI-MS/MS) is a process in which a solution 
containing the analyte, either from a syringe pump 
or as the eluent ﬂ  ow from liquid chromatography 
(in this case known as LC-ESI-MS/MS), is sprayed 
across a high potential difference electrospray 
needle. The charged droplets from the spray are 
desolvated by either countercurrent gas flow 
(present in the opposite direction to the spray) or 
by passage through a heated capillary, a source 
sampling cone; then the resulting ions after desol-
vation of these charged droplets are analyzed in a 
mass spectrometer (Dongre et al. 1997). This is a 
very soft method of ionization where very little 
residual energy is retained by the analyte. This 
shows the importance of ESI-MS as a technique 
in biological studies where the analyst often 
requires that non-covalent molecule-protein or 
protein-protein interactions are representatively 
transferred into the gas-phase. The fact that the 
production of fragmentation is very little, usually 
none is produced, is the major disadvantage of this 
technique. For structural clariﬁ  cation studies, the 
requirement for tandem mass spectrometry is a 
must where the analyte molecules can be frag-
mented. ESI-MS/MS, for instance, was coupled to 
microcapillary reversed-phase
 liquid chromatog-
raphy in a study where the analysis of low molec-
ular weight serum proteome sample
 resulted in the 
identiﬁ  cation of over 340 human serum proteins 
(Tirumalai et al. 2003).
The powerfulness of mass spectrometry has 
been discussed above. The application of mass 
spectrometry for the identification of disease 
biomarkers in serum samples is a growing ﬁ  eld of 
research holding high promise for clinical 
oncology. Serum biomarker proteomics continues 
to evolve and progress following the improvements 
of technology, clinical study design, and bioinfor-
matics (Drake et al. 2006). 
3.2 Immunological techniques
3.2.1 Sandwich Enzyme-Linked 
ImmunoSorbent Assay
A protein identiﬁ  cation method is the “Sandwich” 
Enzyme-Linked ImmunoSorbent Assay (ELISA), 
a fast and accurate biochemical technique very 
useful to detect the presence and determine the 
concentration of low-concentrated antigen or 
antigen contained in high concentrations of 
contaminating protein in unknown samples. The 
sandwich ELISA requires two antibodies that bind 
to epitopes (antigenic sites) that do not have 
common ground on the antigen. This can be accom-
plished with either using two monoclonal anti-
bodies that recognize discrete sites, which allow 
ﬁ  ne detection and quantiﬁ  cation of small differ-
ences in antigen, or using one batch of afﬁ  nity-
puriﬁ  ed polyclonal antibodies to pull down as 
much of the antigen as possible. To quantify the 
assay one should use a colorimetric substrate to 
measure the amount of labeled detection antibody 
bound to the matrix. As the antigen does not need 
to be puriﬁ  ed prior to use and these assays are very 
speciﬁ  c, these facts are considered major advan-
tages of this technique. However, not all antibodies 
can be used. Monoclonal antibody combinations 
must recognize separate epitopes on the antigen so 
they do not hinder each other’s binding and there-
fore be eligible as “matched pairs.” An example of 
a sandwich ELISA kit that detects circulating 
galactomannan is the Platelia Aspergillus, which 
due to the early detection of the antigen has been 
a major advance for managing patients at risk for 
invasive aspergillosis (Mennink-Kersten et al. 
2004). For multiplexed sandwich assays there are 
several labeling and detection methods that can be 
employed (Wodicka et al. 1997; Scorilas et al. 
2000; Moody et al. 2001; Wiese et al. 2001; Huang 
et al. 2001; Wang et al. 2002; Woodbury et al. 2002; 
Tam et al. 2002; Nielsen et al. 2003).
Matrix metalloproteinase-2 (MMP-2) and tissue 
inhibitor of metalloproteinases-2 (TIMP-2) levels 
in patients with systemic sclerosis were determined 
by means of sandwich ELISA in a study that 
concluded that serum TIMP-2 level can be used as 
a marker of the extent of skin sclerosis and disease 
activity added to the fact that TIMP-2 and MMP-2’s 
balance may play an important role in those patients 
(Yazawa et al. 2000). Moreover, another study used 
it to determine that increased pentosidine serum 
concentration in patients
 with osteoarthritis and its 
correlation with the cartilage destruction marker 
COMP (cartilage oligomeric matrix protein) in 
synovial ﬂ  uid suggests that pentosidine may be 
important
 in osteoarthritis pathology and is a new 
potential osteoarthritis marker (Senolt et al. 2005).
3.2.2 Western blot/immunoblot
Another immunological technique, Western blot 
or immunoblot, (Towbin et al. 1979; Burnette, 
1981) is a method in biochemistry/molecular 
biology/immunogenetics to detect speciﬁ  c protein Biomarker Insights 2007: 2 29
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in a given sample of tissue homogenate or extract, 
while giving information about the size of that 
protein and how much protein has accumulated in 
cells. Proteins are electrophoresed into a gel (poly-
acrilamide gels, SDS-PAGE, are most common) 
to separate denatured proteins by size and charge 
and compared to a control, a “marker” or “ladder.” 
Proteins small in size migrate through the gel faster 
than larger ones. The separated proteins in an SDS-
PAGE are then transferred out of the gel and onto 
a membrane, which is in general nitrocellulose or 
PolyVinylidine DiFluoride (a thermoplastic ﬂ  uo-
ropolymer) placed face-to-face with the gel by 
applying an electric current. 
The detection of the membrane-blotted antigen 
requires: ﬁ  rst, the blocking of the sites on the 
membrane that have no blotted protein from the 
gel, the addition and incubation of primary anti-
body with the membrane, which is a sensitive and 
specific detection tool, the addition of the 
secondary antibodies, which are anti-immuno-
globulin antibodies coupled to a reporter group, 
such as to biotin, to alkaline phosphatase, e.g. 
goat anti-human IgG- alkaline phosphatase 
(Wallis et al. 1990), or to horseradish peroxidase, 
and directed against a species-speciﬁ  c portion of 
the primary antibody. 
After excess second antibody is washed away 
from the blot, a substrate is added to the membrane 
and it will be converted by the reporter enzyme to 
a colored reaction product, this will cause the 
speciﬁ  c protein to be detected on the membrane 
to become visible, as in the case of utilizing mono-
clonal antibodies for SERCA 1 (clone IIH11) and 
SERCA 2 (Arruda et al. 2003). In case of a horse-
radish peroxidase-linked secondary antibody, 
which is commonly used in combination with a 
chemiluminescent agent, the reaction product will 
produce ﬂ  uorescence in proportion to the amount 
of speciﬁ  c protein bound. Placing a sensitive sheet 
of photographic ﬁ  lm against the membrane will 
create an image of the antibodies bound to the blot 
upon its exposure to the light from the reaction. 
Another way of detection is by utilizing radioac-
tive labeling (e.g. a radioactive isotope of iodine) 
rather than an enzyme coupled to the secondary 
antibody. This method is highly sensitive, but very 
rarely used as the other non-radioactive methods 
have more advantages of being cheaper, safer, and 
faster. 
Western blot was recently used to conﬁ  rm the 
presence of elevated serum heat shock protein 70 
levels in the patients with sudden sensorineural 
hearing loss compared with normal controls. This 
study suggests that these levels of heat shock 
protein 70 might have a clinical role in predicting 
prognosis of hearing loss in the patients with 
sudden sensorineural hearing loss (Park et al. 
2006). Also, Western blot was used to characterize 
Human Kallikrein 11, suggesting it as a candidate 
prostate and ovarian cancer biomarker, from 
seminal plasma (Luo et al. 2006). Moreover, it was 
utilized to validate that Heat-shock protein 27 is a 
potential biomarker for hepatocellular carcinoma 
and that it could help in the diagnosis of Hepatocel-
lular carcinoma though further validation is needed 
(Feng et al. 2005).
3.3 Multi-dimensional Protein 
Identiﬁ  cation Technology (MudPIT)
Multi-dimensional Protein Identiﬁ  cation Tech-
nology (MudPIT) pioneered by Yates is an 
unbiased method for rapid and large-scale semi-
quantitative proteome analysis and protein 
biomarker candidates identiﬁ  cation (Wolters et al. 
2001; Gao et al. 2005). MudPIT begins with multi-
dimensional liquid chromatography, followed by 
tandem mass spectrometry, and ﬁ  nalizing by a 
database searching by the SEQUEST algorithm 
(Eng et al. 1994; Yates et al. 1995; Washburn et 
al. 2001), where SEQUEST is a database search 
program for performing protein identiﬁ  cation and 
peptide sequencing by utilizing mass spectrometry 
fragmentation patterns to search protein and 
nucleotide databases (Tabb et al. 2001).
MudPIT is another approach which may help 
lessen many of the disadvantages associated with 
two-dimensional gel electrophoresis. The advan-
tage of MudPIT using two chromatography steps 
interfaced back to back in a fused silica capillary 
is that the band broadening associated with many 
chromatographic steps, which can lead to resolu-
tion loss hence the running of components into one 
another, is avoided and also the capillary can be 
placed directly into the ion source of a mass spec-
trometer maximizing sensitivity. The mass spec-
trometer is a tandem electrospray, so peptides are 
ionized in the liquid phase, separated in a primary 
mass spectrometer, broken up using collision 
induced dissociation and analyzed again (Eng et al. 
1994; Link et al. 1999; Gygi et al. 1999; Washburn 
et al. 2001; Han et al. 2001; Ideker et al. 2001; 
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MudPIT was used to resolve and analyze, for 
example, the fractionated serum proteins which 
were trypsinized in an attempt to prove that several 
different prefractionation approaches should be 
used in parallel for a comprehensive identiﬁ  cation 
of the serum proteins (Barnea et al. 2005). The 
Human Proteome Organization in another study 
used MudPIT to perform
 an extensive analysis of 
serum proteins in which they identiﬁ  ed a large
 
number of proteins (490) to further provide the 
foundation for future studies
 with clinically impor-
tant disease states (Adkins et al. 2002). Analysis 
of the tandem mass spectra
 resulted in the identi-
ﬁ  cation of over 340 human serum proteins in a 
study that was trying to prove the efﬁ  cacy
 of having 
Centrifugal ultraﬁ  ltration
 followed by MudPIT for 
the removal of large abundant proteins and
 the 
enrichment of the low molecular weight
 serum 
proteome (Tirumalai et al. 2003).
4. Biomarkers in Serum
4.1 Overview
Serum Prostate-Speciﬁ  c Antigen (PSA) and pros-
tatic acid phosphatase are clinically established 
biomarkers in human serum. While PSA is used 
in insurance testing to assess the risk of under-
lying prostate cancer, other biomarkers are neither 
speciﬁ  c enough nor cost effective to use. Serum-
protein biomarker approvals despite steady 
increases in the literature on potentially useful 
ones have seen a noticeable decrease. Before 
receiving US Food and Drug Administration 
(FDA) approval, biomarker candidates must 
undergo clinical validation. Yet that process is 
just beginning for most candidate markers. More-
over, among the FDA-approved biomarkers (see 
Table 2) only PSA is routinely used in standard 
clinical practice, and only two of the biomarkers 
have made it into the TNM staging guidelines, 
which is based on a combination of Tumor size 
or depth, lymph Node spread, and presence or 
absence of Metastases and provides the following 
information: a) a basis for prediction of survival, 
b) option of initial treatment, c) precise commu-
nication among healthcare providers, d) stratiﬁ  ca-
tion of patients in clinical trials, e) and consistent 
reporting of the end result of cancer management.
The ideal biomarker assay for staging should be 
speciﬁ  c, cost-effective, sensitive, fast, and durable 
against inter-operator and inter-institutional 
variability. It must also display clinical value afar 
that of the other types of information that are 
already available at the time of diagnosis (Ludwig 
and Weinstein, 2005). The following includes a 
discussion of the possible serum biomarkers that 
were found for cancerous and other major 
illnesses.
4.2 Cancer biomarkers
Cancer or tumor markers can be deﬁ  ned as tools 
that clinicians rely upon to answer clinically related 
questions concerning a cancer disease (Diamandis, 
2002). A more preferred speciﬁ  c deﬁ  nition of a 
tumor marker is: a molecule, a process, or a 
substance that
 is altered quantitatively or qualita-
tively in precancerous or
 cancerous conditions, the 
alteration being detectable by an
 assay (Hayes et al. 
1996). The tumor itself or the surrounding normal 
tissue as a response to tumor cells can produce 
those alterations (Hayes et al. 1996). The tumor
 
marker itself can be mRNA, DNA, processes 
(apoptosis,
 angiogenesis, proliferation, etc.), or 
protein measured qualitatively or
 quantitatively by 
a suitable assay, which can be of various formats 
stretching
 from complex animal models to immu-
nohistochemical test kits.
 The immunoassay, a 
well-characterized methodology, is probably the 
most commonly used format. In spite of this, there 
is a rapid progress in this ﬁ  eld, and fresh and 
advanced assays, like microarrays
 and mass spec-
trometry, are becoming established technologies
 
in tumor marker research (Schrohl et al. 2003). In 
the following paragraphs only biomarkers in 
“serum” will be discussed in both cancer and other 
disease cases.
4.2.1 Prostate cancer biomarker
To date, predictive clinical markers in prostate 
cancer are the prostatic acid phosphatase (Gutman 
et al. 1936; Yam, 1974; Vihko, 1979; Lin et al. 
1980; Sakai et al. 1992; Veeramani et al. 2005) and 
serum PSA (Sensabaugh, 1978; Cooper et al. 1990; 
Grignon and Hammond, 1995; Schrohl et al. 2003; 
Veeramani et al. 2005). Other markers have not 
earned sufﬁ  cient support in the literature to be 
recommended for routine clinical application 
(Grignon and Hammond, 1995). Human prostatic 
acid phosphatase was used prior to the availability 
of PSA as a valuable surrogate marker for moni-
toring prostate cancer (Veeramani et al. 2005). 
Although PSA, the tumor-associated serum protein Biomarker Insights 2007: 2 31
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Table 2. FDA-approved and Potential Disease-serum Biomarkers.
Disease  FDA approved  Potential Biomarkers
 Biomarkers
Prostate  PSA  Prostatic acid phosphatase, CK18-Asp396, prostate secretory
    protein of 94 amino acids, hepatocyte growth factor activator,
    insulin-like growth factor binding protein-1 and -3,
    E-cadherin,and alpha-methylacyl-CoA racemase.
Breast CA15.3,  Her-2/neu,  CEA, Human kallikrein genes 5, and serum carboxyterminal
  and CA27–29  telopeptide of type I collagen.
Ovarian  CA125  Isoforms of haptoglobin-1 precursor, hemoglobin-α,
   hemoglobin-β, human kallikrein 6 & 10, Prostasin,
    Osteopontin, Tumor-associated trypsin inhibitor,
    preoperative serum Human Chorionic Gonadotropin-beta,
    Interleukin-8, and serum Carboxy-terminal telopeptide
    of type I collagen.
Lung (non-small   none  CEA and pretreatment serum macrophage colony-stimulating
cell lung cancer)     factor.
Lung (small cell   none  Pro-gastrin-releasing peptide
lung cancer)
Liver none  Alpha-fetoprotein
Non alpha- 
Seminomatous fetoprotein
Testicular   Human corionic
Seminoma gonadotropin-β 
Thyroid Thyroglobulin  MMP-2  and  TIMP-2.
Medullary Thyroid  none  Calcitonin, CEA, and pro-gastrin-releasing peptide.
Melanoma none  Melanoma-inhibiting  activity
Colorectal  none  Human chronic gonadotropin-beta and D-dimer.
Pancreas  CA19–9  Human chronic gonadotropin-beta
Kidney  none  Human chronic gonadotropin-beta
Colon none  CEA
Heart Disease  none  B-type natriuretic peptide, N-terminal pro-B-type natriuretic
    peptide, cardiac troponin T, and high-sensitivity CRP.
Rheumatoid   none  CRP, erythrocyte sedimentation rate, stromelysin-1 (MMP-3),
Arthritis    melanoma-inhibiting activity, CS846-epitope, neoepitope
    marker for degradation of type II collagen in cartilage,
    interleukin-15, cytokines, vascular endothelial growth
    factor, myeloid-related protein 8, CRP, S100A8/calgranulin
    A, S100A9/calgranulin B, S100A12/calgranulin C proteins,
    and serum cartilage oligomeric matrix protein.
Asthma  none  Serum urinary-trypsin-inhibitor, serum esinophil
    cationic protein, and serum tryptase.
Cystic Fibrosis  none  CA 19–9, Trypsinogen, TIMP-1, collagen-IV, and prolyl
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marker, is useful for monitoring prostate cancer 
progression, it is insufficient for diagnosing 
primary cancers or even early prostate cancer 
detection mainly due to its limited speciﬁ  city at 
the desired sensitivity (Pannek and Partin, 1998, 
Djavan et al. 1999; Petricoin et al. 2002b; Adam 
et al. 2002; Qu et al. 2002; Wang et al. 2005; 
Engwegen Judith et al. 2006). 
Identiﬁ  cation of serum biomarkers for prostate 
cancer has been the aim of many studies. In one 
study, caspase-cleaved cytokeratin 18 (CK18-
Asp396) serum marker was used to assess tumor 
apoptosis in vivo (Kramer et al. 2006). In another 
study, serum prostate secretory protein of 94 
amino acids is able to help identify patients with 
high grade prostate cancer (Nam et al. 2006). In 
addition, serum hepatocyte growth factor acti-
vator was elevated in patients with advanced stage 
prostate cancer but further studies are needed to 
verify its clinical value (Nagakawa et al. 2005). 
Serum insulin-like growth factor binding protein-1 
and -3 participate in an important role in regula-
tion of prostate cancer cell growth. Results of 
studying serum insulin-like growth factor binding 
protein-3/PSA ratio suggested that it might be a 
useful prognostic marker in patients with 
advanced prostate cancer (Miyata et al. 2003). 
Moreover, an 80 kDa fragment of e-cadherin was 
believed to be a serum biomarker in a broad 
spectrum of prostate cancer cases (Kuefer et al. 
2005). Today assays are available to detect a 
humoral immune response against alpha-methyl-
acyl-CoA racemase, which may have the potential 
to complement PSA screening in identifying 
patients with clinically signiﬁ  cant prostate cancer 
(Sreekumar et al. 2004).
4.2.2 Breast cancer biomarker
Serum carcinoembryonic antigen (CEA), a glyco-
protein normally found in embryonic endodermal 
epithelium, is elevated in 30–50% of patients with 
symptomatic metastatic breast cancer (Mughal et al. 
1983; Williams et al. 1988; Robertson et al. 1991). 
MUC1 mucin, a glycoprotein, is expressed on the 
apical surface of epithelial cells under normal 
conditions. Only in case of tumors, the disruption 
of the normal tissue architecture due to the growing 
tumor allows MUC1 mucin to be shed into the 
circulation where it can be measured via immuno-
assays kits to detect cancer antigen 15.3 (CA 15.3), 
mucin-like carcinoma associated antigen, breast 
cancer mucin, and the like. Human kallikrein gene
 5 
was also found to be a potential biomarker in 
patients with ovarian and breast
 cancer (Yousef 
et al. 2003).
Currently, many biomarkers, particularly the 
hormonal and epidermal growth factor receptors, 
are utilized for breast cancer prognosis. Together 
with those
 predictive biomarkers (progesterone 
and estrogen receptors) (Schrohl et al. 2003), 
histological grade or Gleason system, axillary 
lymph node status,
 tumor size, and age,
 are 
currently used for selecting the suitable systemic 
therapy. Although none of the biomarkers in use 
have sufﬁ  cient diagnostic, prognostic or predic-
tive power across all categories and stages of 
breast cancer, more useful information can be 
generated if tumors are questioned with multiple 
markers with a right combination for each case, 
which is a challenging matter (Arciero et al. 
2003; Somiari et al. 2005). In a recent study, one 
of the most popular serum biomarkers for the 
follow up of breast cancers and the early detec-
tion of breast cancer metastases is the cancer 
antigen Ca15.3, (Wang et al. 2005; Mathelin et al. 
2006), a carbohydrate antigen commonly known 
as a “mucin,” which inﬂ  uences cell–cell interac-
tion and
 cell growth (Banfi et al. 1997). In 
patients with early stage cancers, however, one 
study shows that Ca15.3 measurements are not 
helpful in diagnosis and the therapeutic decision 
making of patients with breast cancer (Lumachi 
et al. 2004). Her-2/neu, a cell membrane surface-
bound tyrosine kinase, which is involved in the 
signal transduction pathways leading to cell 
growth and differentiation, and a glycoprotein 
MUC1 that can be recognized by CA27–29, a 
monoclonal antibody, are Food and Drug Admin-
istration (FDA) approved cancer biomarkers for 
monitoring breast cancer (Ludwig and Weinstein, 
2005).
In a recent paper the clinical importance of 
serum pro-Iota collagen peptide and serum 
carboxyterminal telopeptide of type I collagen, 
CA15.3 and CEA was evaluated as compared to 
bone scintigraphy to detect metastatic breast 
cancer. It was concluded that combining serum 
CA15.3, carboxyterminal telopeptide of type I, 
and CEA would increase the sensitivity and 
speciﬁ  city of the test, while pro-Iota collagen 
peptide alone or combined with carboxyterminal 
telopeptide of type I were not sensitive (Zissimo-
poulos et al. 2006).Biomarker Insights 2007: 2 33
Serum Biomarkers
4.2.3 Ovarian cancer biomarker
Increased serum levels of CA125 (Whitehouse and 
Solomon, 2003), a mucin-type protein (Lloyd 
et al. 1997) that is often secreted into the blood by 
ovarian cells shed by cancer cells or also made by 
inﬂ  amed normal cells that line body parts, is widely 
used in the clinical setting to monitor ovarian 
cancer patients for early diagnosis of tumor recur-
rence (Bast et al. 1998) and follow-up of patients 
after treatment to calculate response (Rustin et al. 
1999). However, it has low sensitivity and speci-
ﬁ  city and false-positive results can be obtained 
since CA125 is also produced in the ascites, a 
common factor present in both ovarian cancer and 
liver cirrhosis, and therefore the CA125 antigen 
alone can not be of diagnostic use in any patient 
with ascites or pleural effusions (Bergmann et al. 
1986).
Many studies have been performed by different 
groups aiming to uncover serum biomarkers for 
ovarian cancer or even tentative ones for several 
stages of the cancer. One of which showed that 
isoforms of haptoglobin-1 precursor, a liver glyco-
protein present in human serum can be used as a 
serum marker for ovarian cancer early detection 
(Ahmed et al. 2004). Determined by ELISA, two 
ovarian cancer biomarker proteins were discovered 
by another group and identiﬁ  ed as hemoglobin-α 
and hemoglobin-β. But additional studies are 
required to further validate them as biomarkers 
(Ahn et al. 2005). In addition to those, some studies 
found that serum human kallikrein 6 (a serine 
protease) (Diamandis, 2002; Diamandis et al. 2003; 
Bayes et al. 2004; Oikonomopoulou et al. 2006) 
and human kallikrein 10 (Luo et al. 2001) concen-
trations seem to be new biomarkers for ovarian 
carcinoma and may have value for disease diag-
nosis and prognosis. Prostasin, a tryptic peptidase 
expressed in prostate, kidney, lung and airway 
(Tong et al. 2004), is overexpressed in epithelial 
ovarian cancer and should be investigated further 
as a screening or tumor marker, alone and in combi-
nation with CA125 (Mok et al. 2001). Osteopontin, 
a N-linked glycoprotein family of calciﬁ  ed extra-
cellular matrix–associated protein, has been 
discussed as a potential diagnostic biomarker for 
ovarian cancer and showed evidence of an asso-
ciation between levels of osteopontin in serum and 
ovarian cancer suggesting that it would be worth-
while for future research assessing its clinical 
usefulness (Kim et al. 2002; Bramwell et al. 2006). 
Tumor-associated trypsin inhibitor’s elevated level 
is another important predictor of disease stage and 
future prognosis in ovarian cancer (Torre et al. 
1991). Moreover, a study suggested that preopera-
tive serum Human Chorionic Gonadotropin-beta 
is a strong independent prognostic factor in epithe-
lial ovarian carcinoma (Higashida et al. 2001) 
when measured with a sensitive and specific 
method (Vartiainen et al. 2001). Furthermore, 
another study illustrates that Interleukin-8 could 
possibly act as a useful monitoring marker in 
patients with ovarian carcinoma (Mayerhofer et al. 
2001). It was also found that an increased serum 
Carboxyterminal telopeptide of type I collagen 
concentration may reﬂ  ect the spreading and aggres-
siveness of invasively growing ovarian cancer 
making serum Carboxyterminal telopeptide of 
type I collagen a clinically useful predictor of the 
clinical behavior of ovarian cancer (Santala et al. 
2004). 
4.2.4 Lung cancer biomarker
People at high risk for lung cancer have been 
studied in an attempt to identify new biomarkers 
that may be predictive of precancerous lung lesions 
and their possible progression to lung cancer. A 
study showed that serum CEA level could be a 
predictive factor for the efﬁ  cacy of geﬁ  tinib treat-
ment (a drug that is used to treat non-small cell 
lung cancer also is being studied in the treatment 
of other types of cancer) while also considering 
CEA a prognostic factor for advanced non-small 
cell lung cancer patients undergoing this treatment 
(Okamoto et al. 2005). A more recent topic-related 
study revealed that increased pretreatment serum 
macrophage colony-stimulating factor level is a 
signiﬁ  cant independent predictor of poor survival 
in patients with non-small cell lung cancer, where 
CEA levels were shown but couldn’t prove to be 
an independent prognostic factor as macrophage 
colony-stimulating factor did (Kaminska et al. 
2006). Currently, there are no satisfactory 
biomarkers available to screen for lung cancer.
4.2.5 Other cancer biomarkers
In order to improve the prognosis of cancer 
patients, it is crucial to explore serum biomarkers 
for its early diagnosis. One of the serum biomarkers 
is the alpha-fetoprotein for tumors of the liver 
(Johnson et al. 2000; Johnson, 2001), non semino-
matous testis, and other germ cell line tumors. 
Human corionic gonadotropin-β, a glycoprotein, Biomarker Insights 2007: 2 34
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elevated serum level indicates the presence of 
metastatic testicular seminoma tumors but lactic 
acid dehydrogenase serum level, rather than human 
corionic gonadotropin-β, is more useful as a prog-
nostic indicator for those patients with seminoma 
(Hori et al. 1997). Even though serum calcitonin 
and CEA are biomarkers for medullary thyroid 
carcinoma (Hamada et al. 1976), some recent 
studies report that those biomarkers are of no 
clinical use (Bockhorn et al. 2004), while other 
studies add pro-gastrin-releasing peptide, which is 
considered to be a speciﬁ  c marker for small cell 
lung carcinoma, as an additional marker for the 
diagnosis and monitoring the response to therapy 
in patients with medullary thyroid carcinoma (Ide 
et al. 2001). The evaluation of the concentration 
of metalloproteinase-2 and its tissue inhibitor 
TIMP-2 in peripheral blood serum may be useful 
for the differentiation between benign and malig-
nant thyroid tumors, but their concentrations in 
patients with thyroid cancer did not signiﬁ  cantly 
correlate with the clinical staging of thyroid cancer 
(Pasieka et al. 2004). Measuring the levels of 
thyroglobulin, a protein produced by the thyroid 
gland, in the blood have been approved by the FDA 
as a monitoring biomarker for thyroid cancer 
(Ludwig and Weinstein, 2005). In systemic malig-
nant melanoma, melanoma-inhibiting activity was 
found to represent a serum marker for this cancer 
showing a high sensitivity and speciﬁ  city (Bosser-
hoff et al. 1997). A studying group have discussed 
human chronic gonadotropin-beta as being most 
commonly elevated (>10 mIU/ml) in the serum of 
gynecological cancers especially ovarian cancer 
(Higashida et al. 2001), but it is also elevated in 
colorectal (Lundin et al. 2000), pancreas (Syrigos 
et al. 1998), and kidney (Torre et al. 1991), cancers 
and, therefore, can be referred to as a “current 
serum cancer marker.” D-dimer’s elevated levels 
in serum, a ﬁ  brin degradation product, has also 
been proposed as an important prognostic 
biomarker for metastatic colorectal carcinoma 
(Blackwell et al. 2004) but its use is limited by its 
low speciﬁ  city. CEA is reported as a colon cancer 
marker having low speciﬁ  city and insufﬁ  cient 
sensitivity to be used as a screening marker, as it 
can be elevated by many other factors than cancer; 
smoking for instance raises CEA levels, but can be 
helpful in follow-up (Bast et al. 1996; Chatterjee 
and Zetter, 2005). CA19–9, a serum-derived single 
carbohydrate, has been approved by FDA as a 
cancer biomarker for monitoring pancreatic cancer 
(Ludwig and Weinstein, 2005). Comparing serum 
lipoprotein in patients with cancer to non-cancer 
subjects revealed an association of cancer with low 
serum total cholesterol and a characteristic of low 
low-density lipoprotein-cholesterol, low high-
density lipoprotein-cholesterol and relatively high 
serum triglycerides, where the abnormality is a 
common feature of both hematological and solid 
tumors and is not entirely explained by poor nutri-
tion (Fiorenza et al. 2000). Polanski and Anderson 
(2006) have done comprehensive literature review 
and compiled a list of 1261 proteins believed to be 
differentially expressed in human cancer. Among 
them, only nine have been approved as “tumor 
associated antigens” by the FDA, i.e. CEA, Her-
2/neu, bladder tumor antigen, thyroglobulin, alpha-
fetoprotein, PSA, CA125, CA19.9, CA15.3. Only 
a small fraction of proteins are candidate plasma 
biomarkers that could be further evaluated and 
validated for future early cancer detection, prog-
nosis, and monitoring efﬁ  cacy of speciﬁ  c treatment 
options. 
4.3 Biomarkers for other diseases
4.3.1 Heart disease 
B-type natriuretic peptide, nesiritide, was reported 
as a prognostic marker in acute coronary syndromes 
(McCullough et al. 2002). Several likely uses are 
now considered for B-type natriuretic peptide and 
its terminal prohormone fragment, N-terminal pro-
B-type natriuretic peptide, in adults: (I) to examine 
heart failure therapy’s efﬁ  ciency (Troughton et al. 
2000; Rodeheffer, 2004); (II); to predict prognosis 
(Anand et al. 2003; Maisel et al. 2004); (III) to 
check asymptomatic persons at threat for asymp-
tomatic ventricular dysfunction (Nakamura et al. 
2002; Redﬁ  eld et al. 2004); and (IV) to recognize 
the failure of the heart of patients having dyspnea 
or the like symptoms suggesting heart disease 
(McCullough et al. 2002; Maisel et al. 2002). 
Although, there are available commercial kits for 
B-type natriuretic peptide and N-terminal pro-B-
type natriuretic peptide, which makes them candi-
date markers for heart disease in daily practice 
(Nasser et al. 2005), standardization of these assays 
is deficient, diverse cutoff values have been 
reported, and the effect of age, gender (Redﬁ  eld 
et al. 2002), and possibly renal function, on normal 
values (McCullough Peter and Sandberg Keisha, 
2003) may complicate the use of B-type natriuretic Biomarker Insights 2007: 2 35
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peptide as a marker for heart disease. A recent 
study evaluating serum Levels of N-terminal pro-
B-type natriuretic peptide reveal it as an early 
cardiac marker of carbon monoxide poisoning 
(Davutoglu et al. 2006) and of heart toxicity 
caused by amyloidogenic
 light chains (Palladini 
et al. 2003). Another study assessing serum
 N-
terminal pro-B-type natriuretic peptide and 
cardiac troponin T levels and echocardiography 
was recently performed and concluded that their 
simultaneous measurement allows for precise 
acute pulmonary embolism prognosis (Kostrubiec 
et al. 2005). A scientiﬁ  c group hunted to describe 
the relationship between cholesterol and survival 
in patients with chronic heart failure and 
concluded that lower serum total cholesterol is 
independently associated with a worse prognosis 
(Rauchhaus et al. 2003).
Concentrations of C-reactive protein (CRP), 
serum amyloid
 A, and interleukin-6 were increased 
in
 patients with coronary heart disease but failed 
to correlate with acuteness of coronary disease.
 
Therefore, the study concluded that these markers 
might reﬂ  ect the diffuse atherosclerotic process
 in 
the vascular system rather than the degree of local-
ized obstruction
 from coronary lesions (Rifai et al. 
1999). A later study concluded that high-sensitivity 
CRP has a prognostic utility in patients with acute 
coronary
 syndromes, and it is also considered a 
strong independent predictor of future coronary
 
events in seemingly healthy subjects (Rifai and 
Ridker, 2001). Recently, a study veriﬁ  ed that the 
ﬁ  rst paroxysmal episode of lone atrial ﬁ  brillation 
is associated with elevated high-sensitivity CRP 
levels, proposing that high-sensitivity CRP may 
be a marker for inﬂ  ammatory states that may prop 
up the initiation of lone atrial fibrillation 
(Hatzinikolaou-Kotsakou et al. 2006).
4.3.2 Rheumatoid Arthritis (RA)
Persistently active rheumatoid arthritis (RA), in 
most patients, has no early biomarker, and this 
leads to high possibility of joint destruction and 
disability (Liao et al. 2004). Although, available 
biomarkers, like CRP or erythrocyte sedimentation 
rate, offer good correspondence parallel with 
disease activity, yet they do not predict subsequent 
severity (Riel et al. 1998). The evaluation of the 
level of stromelysin-1 (matrix metalloproteinase-3) 
in serum presents a particularly useful marker of 
inﬂ  ammatory activity in the joints of patients with 
RA (Yoshihara et al. 1995; Yamanaka et al. 2000). 
In addition to melanoma-inhibiting activity’s role 
in being a serum marker for progression of malig-
nant melanoma (see 4.2.5), a study revealed that 
it might also be useful in the differential diagnosis 
of RA vs. non-destructive rheumatic diseases via 
checking for the presence of elevated levels of 
melanoma-inhibiting activity in serum, which 
correspondingly means a very likely joint destruc-
tion in RA (Muller-Ladner et al. 1999).
Levels of a marker for aggrecan turnover in 
cartilage (CS846-epitope), which is normally 
found in chondroitin sulfate of the cartilage 
proteoglycan aggrecan, are found to be elevated 
in serum in chronic RA, even though the levels 
are found to be depressed in rapid progressive RA 
(Mansson et al. 1995). Some studies showed that 
a neoepitope marker for degradation of type II 
collagen in cartilage, which was generated by 
collagenases, is increased in the serum and urine 
of patients with RA (Poole et al. 2004) making 
type II collagen in cartilage a speciﬁ  c marker for 
cleavage of type II collagen (Verstappen et al. 
2006). Recent studies show that interleukin-15 
may be used as a marker for the evaluation of 
severity of juvenile rheumatoid arthritis (Cao et al. 
2006). Another study’s evaluation of the degree 
of clinical rheumatoid arthritis activity based on 
the concentrations of cytokines tumor necrosis 
factor-α, interleukins -12, -15, and -18 in serum 
and synovial ﬂ  uid concluded that cytokines concen-
trations could be good indicators of the degree of 
the general activity of RA (Petrovic-Rackov, 
2006). The investigation of matrix metalloprotein-
ases-2, -9, inhibitors of matrix metalloproteinase-1, 
and -2 levels in serum and synovial fluid in 
patients with RA and psoriatic arthritis deduced 
that the evaluation of synovial ﬂ  uid concentrations 
is more reliable than that determined in serum 
(Giannelli et al. 2004). The vascular endothelial 
growth factor can also be detected in serum of
 
patients with RA (Kikuchi et al. 1998; Harada et al. 
1998), where vascular endothelial growth factor 
level is related to RA disease activity, therefore, 
suggesting that vascular endothelial growth factor 
may play some role in the pathogenesis of RA 
(Harada et al. 1998; Sone et al. 2001). Auto-
antibodies to α-enolase, an enzyme of the glyco-
lytic pathway, were found to be present in the sera 
of patients in very early RA cases, therefore, 
having potential diagnostic and prognostic value 
for RA (Saulot et al. 2002).Biomarker Insights 2007: 2 36
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In a recent paper comparing marker proteins in 
serum and synovial ﬂ  uid in patients with advanced 
osteoarthrosis (OA) and RA deduced that the only 
marker protein that revealed distinct higher levels 
in the serum than in the synovial ﬂ  uid was matrix 
metalloproteinase-13, but further investigations 
may provide more information about the value of 
matrix metalloproteinase-13 as a potential marker 
to monitor the course of RA and OA (Andereya 
et al. 2006). Moreover, in another recent study 
myeloid-related protein 8 was conﬁ  rmed by MS/
MS to be present in serum of patients with erosive 
RA (Liao et al. 2004). Additionally, mass spec-
trometry identiﬁ  ed protein biomarkers of disease 
severity in the synovial ﬂ  uid and serum of patients 
with rheumatoid arthritis. Those biomarkers are 
high levels of CRP, S100A8/calgranulin A, 
S100A9/calgranulin B, and S100A12/calgranulin 
C proteins. Those proteins were elevated in the 
serum of patients with erosive disease compared 
to patients with nonerosive RA or healthy indi-
viduals (Liao et al. 2004).
An investigation of whether increased cartilage 
oligomeric matrix protein in serum is a speciﬁ  c 
marker for joint destruction done by comparing 
serum cartilage oligomeric matrix protein between 
patients with RA and patients with other inﬂ  amma-
tory rheumatic diseases with less cartilage-destruc-
tive arthritis was able to conﬁ  rm the conclusion that 
serum cartilage oligomeric matrix protein levels 
are highly speciﬁ  c markers for the cartilage degra-
dation process in RA (Skoumal et al. 2004).
4.3.3 Asthma biomarker 
Neutrophil-mediated inﬂ  ammatory events
 have 
been shown to be involved in exacerbation of 
childhood asthma and that the screening
 of urinary-
trypsin-inhibitor-serum concentrations might be 
useful
 for evaluating the neutrophil-mediated 
inﬂ  ammation in childhood
 asthma attack (Yasui 
et al. 2003). Serum esinophil cationic protein may 
also be used to predict a response to corticosteroid 
therapy in adult patients with asthma (Sorkness 
et al. 2002). Serum tryptase detected with B12 
monoclonal antibody-based immunoﬂ  uoroassay 
has been suggested as a marker of allergic airway 
inﬂ  ammation in asthma (Taira et al. 2002).
4.3.4 Cystic ﬁ  brosis
In Cystic Fibrosis (CF) patients, an elevated level 
of serum CA 19–9 (a tumor-associated antigen) 
concentration have been observed in several 
studies (Duffy et al. 1985; Buamah et al. 1986; 
Roberts et al. 1986). Trypsinogen has been reported 
to be an excellent screening test for CF in young 
infants (Cleghorn et al. 1985). As there is no 
straightforward correlation between CF-transmem-
brane conductance regulator genotype and CF lung 
disease severity, ﬁ  nding of novel therapeutic strat-
egies that can efﬁ  ciently overcome this pathology 
isn’t easy (Kerem et al. 1990). In a recent study 
the elevation of tissue inhibitor of metalloprotein-
ases-1 (TIMP-1), collagen-IV, prolyl hydroxylase 
serum concentrations suggest that these may be 
indicators of hepatic ﬁ  brogenesis in cystic ﬁ  brosis 
(Pereira et al. 2004). 
Conclusions
Human serum is extremely complex thus is the 
most difﬁ  cult protein-containing sample
 to char-
acterize. This review examines the various 
proteomic techniques utilized for each step in the 
process of human serum sample preparation or 
treatment, for its prefractionation or separation, 
and for the analysis to identify the corresponding 
serum biomarkers related to a speciﬁ  c disease or 
during different stages of a disease development. 
The discussed proteomic techniques are utilized 
for identifying protein-based serum biomarkers. 
The importance of biomarker identiﬁ  cation cannot 
be underestimated. A fast growing area of basic, 
translational, and clinical research interest is the 
applications of proteomics techniques to preven-
tive, diagnostic, and prognostic medicine. Protein 
biomarkers could facilitate the early detection of 
the onset of a disease at a curable stage and iden-
tiﬁ  cation of subgroup of patients who respond well 
to certain types of drug treatment from those who 
do not. The knowledge generated may provide 
biochemical indicators for predicting patients’ risk 
for cancer, heart attack, or other diseases and their 
different responses to the same therapy for optimal 
patient care and management. 
Although many serum biomarkers were 
discussed, only a few are FDA approved for disease 
diagnosis and prognosis, including cancer 
biomarkers in human serum, CEA, Her-2/neu, 
bladder tumor antigen, thyroglobulin, alpha-
fetoprotein, PSA, CA125, CA19.9, CA15.3, and 
some other cancer biomarkers, as well as cardio-
vascular disease biomarkers Troponin I and B-type 
natriuretic peptide (for more detailed review, see Biomarker Insights 2007: 2 37
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Polanski and Anderson, 2006). Many biomarkers 
remain to be validated for accurate clinical iden-
tiﬁ  cation of a particular disease. It is more desir-
able to combine different techniques and identify 
a panel of biomarkers to accurately measure the 
disease biomarker levels and establish criteria for 
disease diagnosis and prognosis. Moreover, many 
techniques still lack the proper sensitivity, speci-
ﬁ  city, and reproducibility for the identiﬁ  cation of 
serum or other biomarkers. ELISA is a quantita-
tive assay based on speciﬁ  c antibody-antigen 
binding and is commonly used to analyze 
biomarkers due to its sensitivity, speciﬁ  city, and 
simplicity. Unfortunately, specific antibodies 
against many biomarkers are not available. In 
addition, due to the low abundance of some 
biomarkers, those biomarkers are masked by other 
more abundant proteins, and thus, difﬁ  cult to be 
detected. To enhance future serum biomarker 
identiﬁ  cation, techniques should be improved and 
combinations of different technologies and statis-
tical analysis are required to increase the sensi-
tivity, reproducibility, and speciﬁ  city of biomarker 
detection. 
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